Pharmacogenomics of chemotherapeutic susceptibility and toxicity

Table 1 Genetic polymorphisms that are included as pharmacogenomic information in FDA labels for chemotherapeutic agents

Gene	Drug(s)	Chemotherapeutic response versus toxicity	Reference(s)
In tumor genome
BRAF	Vemurafenib	Response	[82]
KIT	Imatinib	Response	[83]
EGFR	Cetuximab, erlotinib, Gefitinib, panitumumab	Response	[13, 84–86]
KRAS	Cetuximab, panitumumab	Response	[87, 88]
In germline genome
G6PD	Rasburicase	Toxicity	[89]
TPMT	Cisplatin, 6-MP, 6-TG	Toxicity	[25, 90]
UGT1A1	Irinotecan, nilotinib	Toxicity	[28, 91, 92]
DPYD	Capecitabine	Toxicity	[30]

The top half of the table shows tumor genome mutations associated with drug response and the bottom half shows germline mutations associated with drug toxicity.

ISSN: 1756-994X